Is the price fair?
What OMCL's price assumes
Omnicell, Inc. trades at 76.0× earnings against 39.1× for the median Health Information Services name, more expensive than its own group.
76.0
Trailing P/E · Health Information Services median 39.1 · 1.94× the median: the market pays up for this one
- Price / sales
- 1.25
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.4%
Free cash flow yield · Health Information Services median 5.9%
- Growth the price implies
- +2.3%
Growth the price implies · The price pays for +2.3% free cash flow growth a year for a decade; the business has delivered +24% a year over the last three.
Details›
- Price / book2026-Q1
- 1.22
- EV / EBIToperating margin 2.8%: the multiple describes the denominator
- not meaningful
- Healthcare median P/E362 names
- 31.5
- Health Information Services median P/E14 names
- 39.1
- Free cash flow, trailing twelve months
- $114M
- Market capitalisation
- $1.78B
- 3-year revenue growth
- −1.1%
- 3-year free cash flow growth
- +24%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $27.23 |
| Its own P/E history, median | $38.66 |
| Its own P/E history, upper quartile | $42.81 |
| 52-week range | $29.46 – $51.39 |
| Today | $33.43 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #11 of 14 by Smart Score